drugset / Trial / NCT00722917

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

NCT00722917

Phase 2 Terminated 323 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.

Timeline

Start
2008-07
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule 30 mg Oral
Subject TAK-379 Unknown 25 mg Oral
Subject TAK-379 Unknown 100 mg Oral
Subject TAK-379 Unknown 200 mg Oral